Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Newborn | 35 | 2024 | 1410 | 1.640 |
Why?
|
| Sepsis | 6 | 2023 | 101 | 1.520 |
Why?
|
| Hypothermia, Induced | 3 | 2023 | 14 | 1.230 |
Why?
|
| Hypoxia-Ischemia, Brain | 3 | 2023 | 17 | 1.230 |
Why?
|
| Streptococcal Infections | 5 | 2020 | 179 | 1.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 5 | 2023 | 10 | 1.090 |
Why?
|
| Cardiopulmonary Resuscitation | 5 | 2023 | 23 | 1.080 |
Why?
|
| Emergency Medical Services | 5 | 2023 | 26 | 1.070 |
Why?
|
| Streptococcus agalactiae | 5 | 2020 | 197 | 1.050 |
Why?
|
| Asphyxia Neonatorum | 1 | 2023 | 11 | 0.850 |
Why?
|
| Infant | 20 | 2024 | 2145 | 0.830 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 4 | 0.800 |
Why?
|
| Delivery Rooms | 1 | 2021 | 3 | 0.800 |
Why?
|
| Meningitis, Bacterial | 2 | 2020 | 32 | 0.750 |
Why?
|
| Humans | 37 | 2024 | 14077 | 0.710 |
Why?
|
| Neonatal Sepsis | 3 | 2023 | 26 | 0.590 |
Why?
|
| Infant, Newborn, Diseases | 4 | 2022 | 73 | 0.590 |
Why?
|
| Female | 20 | 2024 | 8751 | 0.500 |
Why?
|
| Infant, Premature, Diseases | 2 | 2023 | 17 | 0.500 |
Why?
|
| Tertiary Care Centers | 4 | 2023 | 78 | 0.480 |
Why?
|
| Disease Outbreaks | 3 | 2023 | 111 | 0.470 |
Why?
|
| South Africa | 17 | 2024 | 7312 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 274 | 0.420 |
Why?
|
| Premature Birth | 2 | 2023 | 76 | 0.410 |
Why?
|
| Child | 12 | 2024 | 2180 | 0.410 |
Why?
|
| Pregnancy | 9 | 2023 | 1815 | 0.390 |
Why?
|
| Prospective Studies | 7 | 2024 | 1131 | 0.360 |
Why?
|
| Thienamycins | 1 | 2009 | 6 | 0.340 |
Why?
|
| Klebsiella Infections | 1 | 2009 | 13 | 0.330 |
Why?
|
| Male | 12 | 2021 | 6489 | 0.320 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 12 | 0.310 |
Why?
|
| Gestational Age | 3 | 2023 | 78 | 0.280 |
Why?
|
| Hydrops Fetalis | 1 | 2006 | 3 | 0.280 |
Why?
|
| Parvoviridae Infections | 1 | 2006 | 4 | 0.280 |
Why?
|
| Peritonitis | 1 | 2006 | 5 | 0.280 |
Why?
|
| Parvovirus B19, Human | 1 | 2006 | 5 | 0.280 |
Why?
|
| First Aid | 5 | 2023 | 6 | 0.280 |
Why?
|
| Consensus | 5 | 2023 | 59 | 0.270 |
Why?
|
| Case-Control Studies | 4 | 2020 | 464 | 0.270 |
Why?
|
| Cross Infection | 2 | 2024 | 49 | 0.270 |
Why?
|
| Risk Factors | 4 | 2020 | 1431 | 0.240 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 5 | 0.230 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 14 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2023 | 767 | 0.230 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 4 | 0.230 |
Why?
|
| Pulmonary Surfactants | 1 | 2023 | 8 | 0.230 |
Why?
|
| Hypothermia | 1 | 2023 | 3 | 0.220 |
Why?
|
| Lopinavir | 1 | 2024 | 137 | 0.220 |
Why?
|
| Maternal Death | 1 | 2023 | 25 | 0.220 |
Why?
|
| Ritonavir | 1 | 2024 | 137 | 0.220 |
Why?
|
| HIV Protease Inhibitors | 1 | 2024 | 92 | 0.220 |
Why?
|
| Asphyxia | 1 | 2023 | 5 | 0.220 |
Why?
|
| Meningitis | 1 | 2023 | 23 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 56 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 53 | 0.210 |
Why?
|
| Communicable Diseases | 1 | 2023 | 61 | 0.210 |
Why?
|
| Neuroprotection | 1 | 2022 | 4 | 0.200 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2021 | 5 | 0.200 |
Why?
|
| Brain Diseases | 1 | 2022 | 24 | 0.200 |
Why?
|
| Brain | 1 | 2022 | 53 | 0.200 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 6 | 0.190 |
Why?
|
| Listeriosis | 1 | 2021 | 8 | 0.190 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 25 | 0.190 |
Why?
|
| HIV Infections | 4 | 2023 | 4946 | 0.190 |
Why?
|
| Candidemia | 1 | 2021 | 13 | 0.190 |
Why?
|
| Candida | 1 | 2021 | 24 | 0.190 |
Why?
|
| Growth and Development | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 24 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 23 | 0.180 |
Why?
|
| Infant, Premature | 3 | 2023 | 52 | 0.180 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 3 | 0.180 |
Why?
|
| Deoxycholic Acid | 1 | 2020 | 2 | 0.170 |
Why?
|
| Milk, Human | 1 | 2020 | 22 | 0.170 |
Why?
|
| Amphotericin B | 1 | 2020 | 10 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2020 | 40 | 0.170 |
Why?
|
| Developing Countries | 1 | 2021 | 385 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 103 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2023 | 939 | 0.150 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 22 | 0.150 |
Why?
|
| Infant Mortality | 3 | 2023 | 92 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 68 | 0.140 |
Why?
|
| Child, Preschool | 4 | 2024 | 1675 | 0.130 |
Why?
|
| Adult | 5 | 2023 | 5664 | 0.130 |
Why?
|
| Adolescent | 4 | 2024 | 2858 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1377 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 507 | 0.120 |
Why?
|
| Hospitals | 2 | 2023 | 102 | 0.110 |
Why?
|
| Emergency Treatment | 2 | 2023 | 13 | 0.110 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 1275 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 96 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 56 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 88 | 0.090 |
Why?
|
| Stillbirth | 2 | 2023 | 81 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2023 | 16 | 0.090 |
Why?
|
| Blood Culture | 2 | 2021 | 11 | 0.090 |
Why?
|
| Piperacillin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 7 | 0.080 |
Why?
|
| Prevalence | 2 | 2023 | 1149 | 0.080 |
Why?
|
| Klebsiella | 1 | 2009 | 6 | 0.080 |
Why?
|
| Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
|
| beta-Lactam Resistance | 1 | 2009 | 5 | 0.080 |
Why?
|
| beta-Lactamases | 1 | 2009 | 23 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 131 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 153 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2009 | 149 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2006 | 21 | 0.070 |
Why?
|
| Calcinosis | 1 | 2006 | 11 | 0.070 |
Why?
|
| Meconium | 1 | 2006 | 20 | 0.070 |
Why?
|
| Radiography | 1 | 2006 | 80 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 655 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 42 | 0.060 |
Why?
|
| Dyspnea | 1 | 2023 | 9 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2023 | 13 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 113 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 380 | 0.060 |
Why?
|
| Resuscitation | 1 | 2023 | 18 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 8 | 0.050 |
Why?
|
| Carbapenems | 1 | 2023 | 17 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 237 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2023 | 86 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 260 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2024 | 186 | 0.050 |
Why?
|
| Head | 1 | 2022 | 8 | 0.050 |
Why?
|
| Meningitis, Listeria | 1 | 2021 | 3 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2021 | 29 | 0.050 |
Why?
|
| Candida tropicalis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2021 | 2 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.050 |
Why?
|
| Candida parapsilosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 21 | 0.050 |
Why?
|
| Drug Resistance, Fungal | 1 | 2021 | 13 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2021 | 22 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 46 | 0.050 |
Why?
|
| Candida albicans | 1 | 2021 | 15 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2021 | 44 | 0.050 |
Why?
|
| Birth Weight | 1 | 2021 | 78 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 62 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 532 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2020 | 77 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 230 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 41 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 77 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 190 | 0.040 |
Why?
|
| Perinatal Death | 1 | 2019 | 32 | 0.040 |
Why?
|
| Ureaplasma | 1 | 2019 | 4 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 131 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 32 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 263 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 168 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 149 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 206 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 542 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 867 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 1063 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 183 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2357 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 325 | 0.030 |
Why?
|
| HIV | 1 | 2015 | 380 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 47 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 183 | 0.020 |
Why?
|